Nocion Therapeutics

Please note: The information displayed on this page might be outdated.
Nocion Therapeutics: Nocion Therapeutics is a biopharmaceutical company developing novel small molecule charged sodium channel blockers, “nocions”, that selectively affect actively firing nociceptors to provide targeted, robust and sustained relief for the treatment of serious conditions involving cough, itch, and pain. The company’s mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons. Working with Harvard’s Office of Technology Development, Nocion was founded on an exclusive license to foundational intellectual property from Harvard University and Boston Children’s Hospital.
Characteristics:
Based in...
US - New England
Listing
Private
Website:
Address:
Cambridge, MA
United States

Company Participants at Spring Private Company Showcase

Richard Batycky
Nocion Therapeutics, CEO
Rick has been CEO at Nocion since August 2018. He has over two decades of experience in drug development across an array of platforms and disease states, and has been with several start-ups from founding through acquisition. Most recently, he was the Chief Scientific Officer and a founder of Civitas Therapeutics. Civitas was acquired by Acorda, whereupon he became their Chief Technology Officer and Civitas’ lead asset—a novel dry powder inhalation therapy to treat motor issues in Parkinson’s patients—has been approved by the FDA as InbrijaTM. Rick was previously the Chief Scientific Officer and Sr. Vice President of Research & Development at Pulmatrix. He was previously the Vice President of Research and Development at Alkermes, overseeing many facets of product development across pulmonary, injectable and oral platforms. Rick was an original member of Advanced Inhalation Research (AIR®), where he oversaw product development. Rick held several academic posts prior to joining AIR. He received his B.Sc. in Chemical Engineering from the University of Calgary and his S.M. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

Upcoming Company Event Participation